Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 99

1.

BRCA1-associated and sporadic ovarian carcinomas: outcomes of primary cytoreductive surgery or neoadjuvant chemotherapy.

Gorodnova T, Sokolenko A, Ni V, Ivantsov A, Kotiv K, Petrik S, Amelina I, Berlev I, Imyanitov E.

Int J Gynecol Cancer. 2019 Mar 5. pii: ijgc-2018-000175. doi: 10.1136/ijgc-2018-000175. [Epub ahead of print]

PMID:
30839285
2.

ATM mutation spectrum in Russian children with ataxia-telangiectasia.

Suspitsin E, Sokolenko A, Bizin I, Tumakova A, Guseva M, Sokolova N, Vakhlyarskaya S, Kondratenko I, Imyanitov E.

Eur J Med Genet. 2019 Feb 14. pii: S1769-7212(18)30902-9. doi: 10.1016/j.ejmg.2019.02.003. [Epub ahead of print]

PMID:
30772474
3.

Principles of clinical management of ovarian cancer.

Gorodnova TV, Sokolenko AP, Kuligina E, Berlev IV, Imyanitov EN.

Chin Clin Oncol. 2018 Dec;7(6):56. doi: 10.21037/cco.2018.10.06. Review.

4.

Response to: The GPRC5A frameshift variant c.183del is not associated with increased breast cancer risk in BRCA1 mutation carriers.

Bulanova DR, Helenius M, Sokolenko AP, Kuznetsov SG, Imyanitov EN.

Int J Cancer. 2019 Apr 1;144(7):1758-1760. doi: 10.1002/ijc.32013. Epub 2019 Jan 6. No abstract available.

PMID:
30474109
5.

Efficacy of Neoadjuvant Therapy With Cisplatin Plus Mitomycin C in BRCA1-Mutated Ovarian Cancer.

Gorodnova TV, Kotiv KB, Ivantsov AO, Mikheyeva ON, Mikhailiuk GI, Lisyanskaya AS, Mikaya NA, Guseynov KD, Bondarev NE, Matveyeva NS, Nekrasova EA, Sidoruk AA, Roman LD, Manikhas GM, Belyaev AM, Sokolenko AP, Berlev IV, Imyanitov EN.

Int J Gynecol Cancer. 2018 Oct;28(8):1498-1506. doi: 10.1097/IGC.0000000000001352.

PMID:
30247247
6.

Molecular Diagnostics in Clinical Oncology.

Sokolenko AP, Imyanitov EN.

Front Mol Biosci. 2018 Aug 27;5:76. doi: 10.3389/fmolb.2018.00076. eCollection 2018. Review.

7.

EGFR T790M Mutation in TKI-Naïve Clinical Samples: Frequency, Tissue Mosaicism, Predictive Value and Awareness on Artifacts.

Lavdovskaia ED, Iyevleva AG, Sokolenko AP, Mitiushkina NV, Preobrazhenskaya EV, Tiurin VI, Ivantsov AO, Bizin IV, Stelmakh LV, Moiseyenko FV, Karaseva NA, Orlov SV, Moiseyenko VM, Korzhenevskaya MA, Zaitsev IA, Kozak AR, Chistyakov IV, Akopov AL, Volkov NM, Togo AV, Imyanitov EN.

Oncol Res Treat. 2018;41(10):634-642. doi: 10.1159/000491441. Epub 2018 Aug 27.

PMID:
30145586
8.

"Lazarus Response" to Olaparib in a Virtually Chemonaive Breast Cancer Patient Carrying Gross BRCA2 Gene Deletion.

Moiseyenko VM, Chubenko VA, Moiseyenko FV, Zagorskaya LA, Zaytseva YA, Gesha NE, Zykov EN, Ni VI, Preobrazhenskaya EV, Sokolenko AP, Imyanitov EN.

Cureus. 2018 Feb 4;10(2):e2150. doi: 10.7759/cureus.2150.

9.

Multigene sequencing reveals heterogeneity of NLRP12-related autoinflammatory disorders.

Kostik MM, Suspitsin EN, Guseva MN, Levina AS, Kazantseva AY, Sokolenko AP, Imyanitov EN.

Rheumatol Int. 2018 May;38(5):887-893. doi: 10.1007/s00296-018-4002-8. Epub 2018 Mar 2.

PMID:
29500522
10.

Pattern of TSC1 and TSC2 germline mutations in Russian patients with tuberous sclerosis.

Suspitsin EN, Yanus GA, Dorofeeva MY, Ledashcheva TA, Nikitina NV, Buyanova GV, Saifullina EV, Sokolenko AP, Imyanitov EN.

J Hum Genet. 2018 May;63(5):597-604. doi: 10.1038/s10038-018-0416-0. Epub 2018 Feb 23.

PMID:
29476190
11.

First-Line Cetuximab Monotherapy in KRAS/NRAS/BRAF Mutation-Negative Colorectal Cancer Patients.

Moiseyenko VM, Moiseyenko FV, Yanus GA, Kuligina ES, Sokolenko AP, Bizin IV, Kudriavtsev AA, Aleksakhina SN, Volkov NM, Chubenko VA, Kozyreva KS, Kramchaninov MM, Zhuravlev AS, Shelekhova KV, Pashkov DV, Ivantsov AO, Venina AR, Sokolova TN, Preobrazhenskaya EV, Mitiushkina NV, Togo AV, Iyevleva AG, Imyanitov EN.

Clin Drug Investig. 2018 Jun;38(6):553-562. doi: 10.1007/s40261-018-0629-1.

PMID:
29470838
12.

Spectrum of APC and MUTYH germ-line mutations in Russian patients with colorectal malignancies.

Yanus GA, Akhapkina TA, Ivantsov AO, Preobrazhenskaya EV, Aleksakhina SN, Bizin IV, Sokolenko AP, Mitiushkina NV, Kuligina ES, Suspitsin EN, Venina AR, Holmatov MM, Zaitseva OA, Yatsuk OS, Pashkov DV, Belyaev AM, Togo AV, Imyanitov EN, Iyevleva AG.

Clin Genet. 2018 May;93(5):1015-1021. doi: 10.1111/cge.13228. Epub 2018 Mar 9.

PMID:
29406563
13.

Molecular Tests for the Choice of Cancer Therapy.

Sokolenko AP, Imyanitov EN.

Curr Pharm Des. 2017;23(32):4794-4806. doi: 10.2174/1381612823666170719110125.

PMID:
28721808
14.

Detection of BRCA1 gross rearrangements by droplet digital PCR.

Preobrazhenskaya EV, Bizin IV, Kuligina ES, Shleykina AY, Suspitsin EN, Zaytseva OA, Anisimova EI, Laptiev SA, Gorodnova TV, Belyaev AM, Imyanitov EN, Sokolenko AP.

Breast Cancer Res Treat. 2017 Oct;165(3):765-770. doi: 10.1007/s10549-017-4357-7. Epub 2017 Jun 27.

PMID:
28656489
15.

Multigene testing for breast cancer risk assessment: an illusion of added clinical value.

Sokolenko A, Imyanitov E.

Chin Clin Oncol. 2017 Apr;6(2):15. doi: 10.21037/cco.2017.03.02. No abstract available.

16.

Rapid selection of BRCA1-proficient tumor cells during neoadjuvant therapy for ovarian cancer in BRCA1 mutation carriers.

Sokolenko AP, Savonevich EL, Ivantsov AO, Raskin GA, Kuligina ES, Gorodnova TV, Preobrazhenskaya EV, Kleshchov MA, Tiurin VI, Mukhina MS, Kotiv KB, Shulga AV, Kuznetsov SG, Berlev IV, Imyanitov EN.

Cancer Lett. 2017 Jul 1;397:127-132. doi: 10.1016/j.canlet.2017.03.036. Epub 2017 Apr 1.

PMID:
28377179
17.

BRCA1-deficient breast cancer cell lines are resistant to MEK inhibitors and show distinct sensitivities to 6-thioguanine.

Gu Y, Helenius M, Väänänen K, Bulanova D, Saarela J, Sokolenko A, Martens J, Imyanitov E, Kuznetsov S.

Sci Rep. 2016 Jun 17;6:28217. doi: 10.1038/srep28217.

18.

Evidence for a pathogenic role of BRCA1 L1705P and W1837X germ-line mutations.

Sokolenko AP, Volkov NM, Preobrazhenskaya EV, Suspitsin EN, Garifullina AR, Ivantsov AV, Togo AV, Imyanitov EN.

Mol Biol Rep. 2016 May;43(5):335-8. doi: 10.1007/s11033-016-3968-0. Epub 2016 Mar 7.

PMID:
26951538
19.

[CHEK2-associated hereditary breast cancer].

Bessonov AA, Iyevleva AG, Imyanitov EN, Sokolenko AP.

Vopr Onkol. 2016;62(6):753-757. Review. Russian.

PMID:
30695561
20.

[Whole exome sequencing in oncology].

Suspitsyn EN, Sokolenko AP, Imyanitov EN.

Vopr Onkol. 2016;62(6):713-718. Review. Russian.

PMID:
30695557
21.

Complete Clinical Response of BRAF-Mutated Cholangiocarcinoma to Vemurafenib, Panitumumab, and Irinotecan.

Silkin SV, Startsev SS, Krasnova ME, Raskin GA, Mitiushkina NV, Iyevleva AG, Sokolenko AP, Imyanitov EN.

J Gastrointest Cancer. 2016 Dec;47(4):502-505. No abstract available.

PMID:
26687137
22.

Exome Sequencing of a Family with Bardet-Biedl Syndrome Identifies the Common Russian Mutation c.1967_1968delTAinsC in BBS7.

Suspitsin EN, Sokolenko AP, Lyazina LV, Preobrazhenskaya EV, Lepenchuk AY, Imyanitov EN.

Mol Syndromol. 2015 Jul;6(2):96-8. doi: 10.1159/000371408. Epub 2015 Jan 24.

23.

Identification of novel hereditary cancer genes by whole exome sequencing.

Sokolenko AP, Suspitsin EN, Kuligina ESh, Bizin IV, Frishman D, Imyanitov EN.

Cancer Lett. 2015 Dec 28;369(2):274-88. doi: 10.1016/j.canlet.2015.09.014. Epub 2015 Sep 30. Review.

PMID:
26427841
24.

High response rates to neoadjuvant platinum-based therapy in ovarian cancer patients carrying germ-line BRCA mutation.

Gorodnova TV, Sokolenko AP, Ivantsov AO, Iyevleva AG, Suspitsin EN, Aleksakhina SN, Yanus GA, Togo AV, Maximov SY, Imyanitov EN.

Cancer Lett. 2015 Dec 28;369(2):363-7. doi: 10.1016/j.canlet.2015.08.028. Epub 2015 Sep 2.

PMID:
26342406
25.

Novel ALK fusion partners in lung cancer.

Iyevleva AG, Raskin GA, Tiurin VI, Sokolenko AP, Mitiushkina NV, Aleksakhina SN, Garifullina AR, Strelkova TN, Merkulov VO, Ivantsov AO, Kuligina ESh, Pozharisski KM, Togo AV, Imyanitov EN.

Cancer Lett. 2015 Jun 28;362(1):116-21. doi: 10.1016/j.canlet.2015.03.028. Epub 2015 Mar 23.

PMID:
25813404
26.

High efficacy of cisplatin neoadjuvant therapy in a prospective series of patients carrying BRCA1 germ-line mutation.

Moiseyenko VM, Dolmatov GD, Moiseyenko FV, Ivantsov AO, Volkov NM, Chubenko VA, Abduloeva NKh, Bogdanov AA, Sokolenko AP, Imyanitov EN.

Med Oncol. 2015 Apr;32(4):89. doi: 10.1007/s12032-015-0514-1. Epub 2015 Feb 25.

PMID:
25711630
27.

Candidate gene analysis of BRCA1/2 mutation-negative high-risk Russian breast cancer patients.

Sokolenko AP, Preobrazhenskaya EV, Aleksakhina SN, Iyevleva AG, Mitiushkina NV, Zaitseva OA, Yatsuk OS, Tiurin VI, Strelkova TN, Togo AV, Imyanitov EN.

Cancer Lett. 2015 Apr 10;359(2):259-61. doi: 10.1016/j.canlet.2015.01.022. Epub 2015 Jan 22.

PMID:
25619955
28.

Breast cancer sensitivity to neoadjuvant therapy in BRCA1 and CHEK2 mutation carriers and non-carriers.

Pfeifer W, Sokolenko AP, Potapova ON, Bessonov AA, Ivantsov AO, Laptiev SA, Zaitseva OA, Yatsuk OS, Matsko DE, Semiglazova TY, Togo AV, Imyanitov EN.

Breast Cancer Res Treat. 2014 Dec;148(3):675-83. doi: 10.1007/s10549-014-3206-1. Epub 2014 Nov 21.

PMID:
25414026
29.

Evidence for clinical efficacy of mitomycin C in heavily pretreated ovarian cancer patients carrying germ-line BRCA1 mutation.

Moiseyenko VM, Chubenko VA, Moiseyenko FV, Zhabina AS, Gorodnova TV, Komarov YI, Bogdanov AA, Sokolenko AP, Imyanitov EN.

Med Oncol. 2014 Oct;31(10):199. doi: 10.1007/s12032-014-0199-x. Epub 2014 Sep 4.

PMID:
25186150
30.

Prevalence of the BLM nonsense mutation, p.Q548X, in ovarian cancer patients from Central and Eastern Europe.

Bogdanova N, Togo AV, Ratajska M, Kluźniak W, Takhirova Z, Tarp T, Prokofyeva D, Bermisheva M, Yanus GA, Gorodnova TV, Sokolenko AP, Kuźniacka A, Podolak A, Stukan M, Wokołorczyk D, Gronwald J, Vasilevska D, Rudaitis V, Runnebaum IB, Dürst M, Park-Simon TW, Hillemanns P, Antonenkova N, Khusnutdinova E, Limon J, Lubinski J, Cybulski C, Imyanitov E, Dörk T.

Fam Cancer. 2015 Mar;14(1):145-9. doi: 10.1007/s10689-014-9748-x.

PMID:
25182961
31.

Double heterozygotes among breast cancer patients analyzed for BRCA1, CHEK2, ATM, NBN/NBS1, and BLM germ-line mutations.

Sokolenko AP, Bogdanova N, Kluzniak W, Preobrazhenskaya EV, Kuligina ES, Iyevleva AG, Aleksakhina SN, Mitiushkina NV, Gorodnova TV, Bessonov AA, Togo AV, Lubiński J, Cybulski C, Jakubowska A, Dörk T, Imyanitov EN.

Breast Cancer Res Treat. 2014 Jun;145(2):553-62. doi: 10.1007/s10549-014-2971-1. Epub 2014 May 7.

PMID:
24800916
32.

High prevalence of GPRC5A germline mutations in BRCA1-mutant breast cancer patients.

Sokolenko AP, Bulanova DR, Iyevleva AG, Aleksakhina SN, Preobrazhenskaya EV, Ivantsov AO, Kuligina ESh, Mitiushkina NV, Suspitsin EN, Yanus GA, Zaitseva OA, Yatsuk OS, Togo AV, Kota P, Dixon JM, Larionov AA, Kuznetsov SG, Imyanitov EN.

Int J Cancer. 2014 May 15;134(10):2352-8. doi: 10.1002/ijc.28569. Epub 2014 Jan 27.

33.

Development of breast tumors in CHEK2, NBN/NBS1 and BLM mutation carriers does not commonly involve somatic inactivation of the wild-type allele.

Suspitsin EN, Yanus GA, Sokolenko AP, Yatsuk OS, Zaitseva OA, Bessonov AA, Ivantsov AO, Heinstein VA, Klimashevskiy VF, Togo AV, Imyanitov EN.

Med Oncol. 2014 Feb;31(2):828. doi: 10.1007/s12032-013-0828-9. Epub 2014 Jan 12.

PMID:
24415413
34.

Evidence for angiogenesis-independent contribution of VEGFR1 (FLT1) in gastric cancer recurrence.

Suspitsin EN, Kashyap A, Shelekhova KV, Sokolenko AP, Kuligina ESh, Iyevleva AG, Kornilov AV, Ehemann V, Yanus GA, Aleksakhina SN, Preobrazhenskaya EV, Zaitseva OA, Yatsuk OS, Klimashevsky VF, Togo AV, Imyanitov EN.

Med Oncol. 2013;30(3):644. doi: 10.1007/s12032-013-0644-2. Epub 2013 Jun 26.

PMID:
23801279
35.

Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk.

Couch FJ, Wang X, McGuffog L, Lee A, Olswold C, Kuchenbaecker KB, Soucy P, Fredericksen Z, Barrowdale D, Dennis J, Gaudet MM, Dicks E, Kosel M, Healey S, Sinilnikova OM, Lee A, Bacot F, Vincent D, Hogervorst FB, Peock S, Stoppa-Lyonnet D, Jakubowska A; kConFab Investigators, Radice P, Schmutzler RK; SWE-BRCA, Domchek SM, Piedmonte M, Singer CF, Friedman E, Thomassen M; Ontario Cancer Genetics Network, Hansen TV, Neuhausen SL, Szabo CI, Blanco I, Greene MH, Karlan BY, Garber J, Phelan CM, Weitzel JN, Montagna M, Olah E, Andrulis IL, Godwin AK, Yannoukakos D, Goldgar DE, Caldes T, Nevanlinna H, Osorio A, Terry MB, Daly MB, van Rensburg EJ, Hamann U, Ramus SJ, Toland AE, Caligo MA, Olopade OI, Tung N, Claes K, Beattie MS, Southey MC, Imyanitov EN, Tischkowitz M, Janavicius R, John EM, Kwong A, Diez O, Balmaña J, Barkardottir RB, Arun BK, Rennert G, Teo SH, Ganz PA, Campbell I, van der Hout AH, van Deurzen CH, Seynaeve C, Gómez Garcia EB, van Leeuwen FE, Meijers-Heijboer HE, Gille JJ, Ausems MG, Blok MJ, Ligtenberg MJ, Rookus MA, Devilee P, Verhoef S, van Os TA, Wijnen JT; HEBON; EMBRACE, Frost D, Ellis S, Fineberg E, Platte R, Evans DG, Izatt L, Eeles RA, Adlard J, Eccles DM, Cook J, Brewer C, Douglas F, Hodgson S, Morrison PJ, Side LE, Donaldson A, Houghton C, Rogers MT, Dorkins H, Eason J, Gregory H, McCann E, Murray A, Calender A, Hardouin A, Berthet P, Delnatte C, Nogues C, Lasset C, Houdayer C, Leroux D, Rouleau E, Prieur F, Damiola F, Sobol H, Coupier I, Venat-Bouvet L, Castera L, Gauthier-Villars M, Léoné M, Pujol P, Mazoyer S, Bignon YJ; GEMO Study Collaborators, Złowocka-Perłowska E, Gronwald J, Lubinski J, Durda K, Jaworska K, Huzarski T, Spurdle AB, Viel A, Peissel B, Bonanni B, Melloni G, Ottini L, Papi L, Varesco L, Tibiletti MG, Peterlongo P, Volorio S, Manoukian S, Pensotti V, Arnold N, Engel C, Deissler H, Gadzicki D, Gehrig A, Kast K, Rhiem K, Meindl A, Niederacher D, Ditsch N, Plendl H, Preisler-Adams S, Engert S, Sutter C, Varon-Mateeva R, Wappenschmidt B, Weber BH, Arver B, Stenmark-Askmalm M, Loman N, Rosenquist R, Einbeigi Z, Nathanson KL, Rebbeck TR, Blank SV, Cohn DE, Rodriguez GC, Small L, Friedlander M, Bae-Jump VL, Fink-Retter A, Rappaport C, Gschwantler-Kaulich D, Pfeiler G, Tea MK, Lindor NM, Kaufman B, Shimon Paluch S, Laitman Y, Skytte AB, Gerdes AM, Pedersen IS, Moeller ST, Kruse TA, Jensen UB, Vijai J, Sarrel K, Robson M, Kauff N, Mulligan AM, Glendon G, Ozcelik H, Ejlertsen B, Nielsen FC, Jønson L, Andersen MK, Ding YC, Steele L, Foretova L, Teulé A, Lazaro C, Brunet J, Pujana MA, Mai PL, Loud JT, Walsh C, Lester J, Orsulic S, Narod SA, Herzog J, Sand SR, Tognazzo S, Agata S, Vaszko T, Weaver J, Stavropoulou AV, Buys SS, Romero A, de la Hoya M, Aittomäki K, Muranen TA, Duran M, Chung WK, Lasa A, Dorfling CM, Miron A; BCFR, Benitez J, Senter L, Huo D, Chan SB, Sokolenko AP, Chiquette J, Tihomirova L, Friebel TM, Agnarsson BA, Lu KH, Lejbkowicz F, James PA, Hall P, Dunning AM, Tessier D, Cunningham J, Slager SL, Wang C, Hart S, Stevens K, Simard J, Pastinen T, Pankratz VS, Offit K, Easton DF, Chenevix-Trench G, Antoniou AC; CIMBA.

PLoS Genet. 2013;9(3):e1003212. doi: 10.1371/journal.pgen.1003212. Epub 2013 Mar 27.

36.

Value of bilateral breast cancer for identification of rare recessive at-risk alleles: evidence for the role of homozygous GEN1 c.2515_2519delAAGTT mutation.

Kuligina ESh, Sokolenko AP, Mitiushkina NV, Abysheva SN, Preobrazhenskaya EV, Gorodnova TV, Yanus GA, Togo AV, Cherdyntseva NV, Bekhtereva SA, Dixon JM, Larionov AA, Kuznetsov SG, Imyanitov EN.

Fam Cancer. 2013 Mar;12(1):129-32. doi: 10.1007/s10689-012-9575-x.

PMID:
23104382
37.

Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA).

Mavaddat N, Barrowdale D, Andrulis IL, Domchek SM, Eccles D, Nevanlinna H, Ramus SJ, Spurdle A, Robson M, Sherman M, Mulligan AM, Couch FJ, Engel C, McGuffog L, Healey S, Sinilnikova OM, Southey MC, Terry MB, Goldgar D, O'Malley F, John EM, Janavicius R, Tihomirova L, Hansen TV, Nielsen FC, Osorio A, Stavropoulou A, Benítez J, Manoukian S, Peissel B, Barile M, Volorio S, Pasini B, Dolcetti R, Putignano AL, Ottini L, Radice P, Hamann U, Rashid MU, Hogervorst FB, Kriege M, van der Luijt RB; HEBON, Peock S, Frost D, Evans DG, Brewer C, Walker L, Rogers MT, Side LE, Houghton C; EMBRACE, Weaver J, Godwin AK, Schmutzler RK, Wappenschmidt B, Meindl A, Kast K, Arnold N, Niederacher D, Sutter C, Deissler H, Gadzicki D, Preisler-Adams S, Varon-Mateeva R, Schönbuchner I, Gevensleben H, Stoppa-Lyonnet D, Belotti M, Barjhoux L; GEMO Study Collaborators, Isaacs C, Peshkin BN, Caldes T, de la Hoya M, Cañadas C, Heikkinen T, Heikkilä P, Aittomäki K, Blanco I, Lazaro C, Brunet J, Agnarsson BA, Arason A, Barkardottir RB, Dumont M, Simard J, Montagna M, Agata S, D'Andrea E, Yan M, Fox S; kConFab Investigators, Rebbeck TR, Rubinstein W, Tung N, Garber JE, Wang X, Fredericksen Z, Pankratz VS, Lindor NM, Szabo C, Offit K, Sakr R, Gaudet MM, Singer CF, Tea MK, Rappaport C, Mai PL, Greene MH, Sokolenko A, Imyanitov E, Toland AE, Senter L, Sweet K, Thomassen M, Gerdes AM, Kruse T, Caligo M, Aretini P, Rantala J, von Wachenfeld A, Henriksson K; SWE-BRCA Collaborators, Steele L, Neuhausen SL, Nussbaum R, Beattie M, Odunsi K, Sucheston L, Gayther SA, Nathanson K, Gross J, Walsh C, Karlan B, Chenevix-Trench G, Easton DF, Antoniou AC; Consortium of Investigators of Modifiers of BRCA1/2.

Cancer Epidemiol Biomarkers Prev. 2012 Jan;21(1):134-47. doi: 10.1158/1055-9965.EPI-11-0775. Epub 2011 Dec 5.

38.

High prevalence and breast cancer predisposing role of the BLM c.1642 C>T (Q548X) mutation in Russia.

Sokolenko AP, Iyevleva AG, Preobrazhenskaya EV, Mitiushkina NV, Abysheva SN, Suspitsin EN, Kuligina ESh, Gorodnova TV, Pfeifer W, Togo AV, Turkevich EA, Ivantsov AO, Voskresenskiy DV, Dolmatov GD, Bit-Sava EM, Matsko DE, Semiglazov VF, Fichtner I, Larionov AA, Kuznetsov SG, Antoniou AC, Imyanitov EN.

Int J Cancer. 2012 Jun 15;130(12):2867-73. doi: 10.1002/ijc.26342. Epub 2011 Oct 20.

39.

PALB2 mutations in German and Russian patients with bilateral breast cancer.

Bogdanova N, Sokolenko AP, Iyevleva AG, Abysheva SN, Blaut M, Bremer M, Christiansen H, Rave-Fränk M, Dörk T, Imyanitov EN.

Breast Cancer Res Treat. 2011 Apr;126(2):545-50. doi: 10.1007/s10549-010-1290-4. Epub 2010 Dec 17.

40.

Hereditary breast-ovarian cancer syndrome in Russia.

Sokolenko AP, Iyevleva AG, Mitiushkina NV, Suspitsin EN, Preobrazhenskaya EV, Kuligina ESh, Voskresenskiy DA, Lobeiko OS, Krylova NY, Gorodnova TV, Buslov KG, Bit-Sava EM, Dolmatov GD, Porhanova NV, Polyakov IS, Abysheva SN, Katanugina AS, Baholdin DV, Yanus GA, Togo AV, Moiseyenko VM, Maximov SY, Semiglazov VF, Imyanitov EN.

Acta Naturae. 2010 Oct;2(4):31-5.

41.

Non-founder BRCA1 mutations in Russian breast cancer patients.

Iyevleva AG, Suspitsin EN, Kroeze K, Gorodnova TV, Sokolenko AP, Buslov KG, Voskresenskiy DA, Togo AV, Kovalenko SP, Stoep Nv, Devilee P, Imyanitov EN.

Cancer Lett. 2010 Dec 8;298(2):258-63. doi: 10.1016/j.canlet.2010.07.013. Epub 2010 Aug 19.

PMID:
20727672
42.

High sensitivity of BRCA1-associated tumors to cisplatin monotherapy: report of two cases.

Moiseyenko VM, Protsenko SA, Brezhnev NV, Maximov SY, Gershveld ED, Hudyakova MA, Lobeiko OS, Gergova MM, Krzhivitskiy PI, Semionov II, Matsko DE, Iyevleva AG, Sokolenko AP, Sherina NY, Kuligina ESh, Suspitsin EN, Togo AV, Imyanitov EN.

Cancer Genet Cytogenet. 2010 Feb;197(1):91-4. doi: 10.1016/j.cancergencyto.2009.10.003. No abstract available.

PMID:
20113845
43.

[The effects of Celebrex on mammary tumorigenesis and aging in HER2/neu transgenic mice].

Piskunova TS, Suspitsin EN, Sokolenko AP, Zabezhinskiĭ MA, Imianitov EI, Semenchenko AV, Anisimov VN.

Vopr Onkol. 2009;55(1):89-92. Russian.

PMID:
19435207
44.

Mixed epithelial/mesenchymal metaplastic carcinoma (carcinosarcoma) of the breast in BRCA1 carrier.

Suspitsin EN, Sokolenko AP, Voskresenskiy DA, Ivantsov AO, Shelehova KV, Klimashevskiy VF, Matsko DE, Semiglazov VF, Imyanitov EN.

Breast Cancer. 2011 Apr;18(2):137-40. doi: 10.1007/s12282-009-0105-0. Epub 2009 Apr 7.

PMID:
19350356
45.

High frequency of BRCA1, but not CHEK2 or NBS1 (NBN), founder mutations in Russian ovarian cancer patients.

Suspitsin EN, Sherina NY, Ponomariova DN, Sokolenko AP, Iyevleva AG, Gorodnova TV, Zaitseva OA, Yatsuk OS, Togo AV, Tkachenko NN, Shiyanov GA, Lobeiko OS, Krylova NY, Matsko DE, Maximov SY, Urmancheyeva AF, Porhanova NV, Imyanitov EN.

Hered Cancer Clin Pract. 2009 Feb 25;7(1):5. doi: 10.1186/1897-4287-7-5.

46.

Large family with both parents affected by distinct BRCA1 mutations: implications for genetic testing.

Sokolenko AP, Voskresenskiy DA, Iyevleva AG, Bit-Sava EM, Gutkina NI, Anisimenko MS, Yu Sherina N, Mitiushkina NV, Ulibina YM, Yatsuk OS, Zaitseva OA, Suspitsin EN, Togo AV, Pospelov VA, Kovalenko SP, Semiglazov VF, Imyanitov EN.

Hered Cancer Clin Pract. 2009 Jan 26;7(1):2. doi: 10.1186/1897-4287-7-2.

47.

Family history, genetic testing, and clinical risk prediction: pooled analysis of CHEK2 1100delC in 1,828 bilateral breast cancers and 7,030 controls.

Fletcher O, Johnson N, Dos Santos Silva I, Kilpivaara O, Aittomäki K, Blomqvist C, Nevanlinna H, Wasielewski M, Meijers-Heijerboer H, Broeks A, Schmidt MK, Van't Veer LJ, Bremer M, Dörk T, Chekmariova EV, Sokolenko AP, Imyanitov EN, Hamann U, Rashid MU, Brauch H, Justenhoven C, Ashworth A, Peto J.

Cancer Epidemiol Biomarkers Prev. 2009 Jan;18(1):230-4. doi: 10.1158/1055-9965.EPI-08-0416.

48.

Ovarian cancer patient with germline mutations in both BRCA1 and NBN genes.

Porhanova NV, Sokolenko AP, Sherina NY, Ponomariova DN, Tkachenko NN, Matsko DE, Imyanitov EN.

Cancer Genet Cytogenet. 2008 Oct 15;186(2):122-4. doi: 10.1016/j.cancergencyto.2008.06.012. No abstract available.

PMID:
18940477
49.

Founder mutations in early-onset, familial and bilateral breast cancer patients from Russia.

Sokolenko AP, Rozanov ME, Mitiushkina NV, Sherina NY, Iyevleva AG, Chekmariova EV, Buslov KG, Shilov ES, Togo AV, Bit-Sava EM, Voskresenskiy DA, Chagunava OL, Devilee P, Cornelisse C, Semiglazov VF, Imyanitov EN.

Fam Cancer. 2007;6(3):281-6. Epub 2007 Feb 28.

PMID:
17333477
50.

Nonrandom distribution of oncogene amplifications in bilateral breast carcinomas: Possible role of host factors and survival bias.

Suspitsin EN, Sokolenko AP, Togo AV, Lazareva YR, Turkevich EA, Matsko DE, Henrich KO, Borresen-Dale AL, Schwab M, Cornelisse CJ, Imyanitov EN.

Int J Cancer. 2007 Jan 15;120(2):297-302.

Supplemental Content

Loading ...
Support Center